Notice2026-16257
Office of the Director, Notice of Charter Renewal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 10, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 152 (Monday, August 10, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 152 (Monday, August 10, 2026)]
[Notices]
[Pages 51499-51501]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-16257]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, Notice of Charter Renewal
In accordance with Title 41 of the U.S. Code of Federal
Regulations, Section 102-3.65(a), notice is hereby given that the
charter for the Fogarty International Center Advisory Board (FICAB) is
being renewed for an additional two-year period on August 31, 2026.
It is determined that the FICAB is in the public interest in
connection with the performance of duties imposed on the National
Institutes of Health by law, and that these duties can best be
performed through the advice and counsel of this group.
The Public Interest Determination follows:
National Institutes of Health Fogarty International Center Advisory
Board Public Interest Determination
Pursuant to 41 CFR 102-3.60(a), to establish, renew, reestablish,
or merge a discretionary (agency discretion) advisory committee, an
agency must first consult with the General Services Administration's
Committee Management Secretariat (the Secretariat) and, as part of the
consultation, provide a written public interest determination approved
by the head of the agency to the Secretariat with a copy to the Office
of Management and Budget. In addition, pursuant to 41 CFR 102-3.35, an
agency shall follow the same consultation process and document in
writing the same determination of need before creating a subcommittee
under a discretionary committee that is not made up entirely of members
of a parent advisory committee.
Information on the following factors for the committee is provided
to the Secretariat to demonstrate that renewing the committee is in the
public interest:
1. Annual budget: The annual budget for the committee is $151,338.
a. Federal personnel on a full-time equivalent (FTE) basis: Federal
personnel (based on full-time equivalent (FTE) usage basis) and other
Federal internal costs. The estimated annual person years of staff
support are .7 at an estimated cost of $130,780.
b. Other Federal internal costs: The estimate for other Federal
internal costs is 0.
c. Proposed payments to members: The estimated payment for non-
Federal members is $6,400 and the estimated prorated salary for Federal
members is $3,740.
d. Proposed number of members: The Board will consist of not more
than 13 members appointed by the Secretary and the following nonvoting
ex officio members: the Directors of 2 NIH institutes or centers with
active international programs and any additional officers or employees
of the United States as the Secretary determines necessary for the
Board to effectively carry out its functions.
e. Reimbursable costs: The estimate for reimbursable costs,
including members' travel expenses, is $10,418.
2. If applicable, the total dollar value of grants expected to be
recommended during the fiscal year:
During the FY25 reporting period, FICAB reviewed 143 applications
for programs, requesting $52,043,864. NIH is unable to project an
amount as the number of awards made are contingent on a variety of
factors, such as annual appropriations, number of applications
received, NIH research priorities, etc.
3. Criteria for selecting members to ensure the committee has the
necessary expertise and fairly balanced membership:
The Board shall consist of not more than 13 members appointed by
the Secretary and Federal ex officio members. Non-Federal members must
be eligible to serve as Special Government Employees (SGEs) and will
serve as SGEs, as defined by 18 U.S.C. 202.
The Chair of the Board will be selected by the Secretary from among
the appointed members, except that the Secretary may select the
Director, FIC, to be the Chair.
The term of office of the Chair will be two years.
Of the 13 appointed members, 10 shall be selected from among the
leading representatives of the health and scientific disciplines
relevant to the activities of the FIC, particularly representatives of
the biomedical and behavioral fields, such as molecular and cellular
biology, neurosciences, basic physiology, epidemiology, immunology,
nutrition, public health, economics, and demography. Three members
shall be appointed by the Secretary from the general public and shall
include leaders in the fields of health-related enterprises such as
pharmaceutical or life insurance companies, voluntary organizations
committed to betterment of public health, international health, and
international health law.
Non-Federal members will be invited to serve for overlapping four-
year terms, except that any member appointed to fill a vacancy for an
unexpired term will be appointed for the remainder of that term. The
Secretary shall make appointments in such a manner as to ensure that
the terms of the appointed members do not all expire in the same year.
An appointed member may serve 180 days after the expiration of that
member's term if a successor has not taken office. A member who has
been appointed for a term of four years may not be reappointed to this
Board before two years from the date of expiration of that member's
term of office.
Nonvoting ex officio members will include the Directors of 2 NIH
institutes or centers with active international programs and any
additional officers or employees of the United States as the Secretary
determines necessary for the Board to effectively carry out its
functions.
4. List of all other Federal advisory committees of the agency:
<bullet> Advisory Committee on Research on Women's Health
<bullet> Advisory Committee to the Director, National Institutes of
Health
<bullet> Advisory Council on Parkinson's Research, Care and Services
<bullet> Aging and Neurodegeneration Integrated Review Group
<bullet> AIDS Research Advisory Committee, NIAID
[[Page 51500]]
<bullet> Applied Immunology and Disease Control Integrated Review Group
<bullet> Applied Therapeutics for Cancer Integrated Review Group
<bullet> Biobehavioral and Behavioral Processes Integrated Review Group
<bullet> Bioengineering Sciences & Technologies Integrated Review Group
<bullet> Biological Chemistry and Macromolecular Biophysics Integrated
Review Group
<bullet> Board of Regents of the National Library of Medicine
<bullet> Board of Scientific Counselors Eunice Kennedy Shriver National
Institute of Child Health and Human Development
<bullet> Board of Scientific Counselors National Human Genome Research
Institute
<bullet> Board of Scientific Counselors of the National Heart, Lung,
and Blood Institute
<bullet> Board of Scientific Counselors of the NIH Clinical Center
<bullet> Board of Scientific Counselors, Division of Translational
Toxicology
<bullet> Board of Scientific Counselors, National Cancer Institute
<bullet> Board of Scientific Counselors, National Center for
Complementary and Integrative Health
<bullet> Board of Scientific Counselors, National Eye Institute
<bullet> Board of Scientific Counselors, National Institute of
Arthritis and Musculoskeletal and Skin Diseases
<bullet> Board of Scientific Counselors, National Institute of
Biomedical Imaging and Bioengineering
<bullet> Board of Scientific Counselors, National Institute of Dental
and Craniofacial Research
<bullet> Board of Scientific Counselors, National Institute of Diabetes
and Digestive and Kidney Diseases
<bullet> Board of Scientific Counselors, National Institute of
Environmental Health Sciences
<bullet> Board of Scientific Counselors, National Institute of Mental
Health
<bullet> Board of Scientific Counselors, National Institute of
Neurological Disorders and Stroke
<bullet> Board of Scientific Counselors, National Institute on Aging
<bullet> Board of Scientific Counselors, National Institute on Alcohol
Abuse and Alcoholism
<bullet> Board of Scientific Counselors, National Institute on Deafness
and Other Communication Disorders
<bullet> Board of Scientific Counselors, National Institute on Drug
Abuse
<bullet> Board of Scientific Counselors, National Institute on Minority
Health and Health Disparities and National Institute of Nursing
Research
<bullet> Board of Scientific Counselors, National Library of Medicine
<bullet> Brain Disorders and Clinical Neuroscience Integrated Review
Group
<bullet> Cardiovascular and Respiratory Sciences Integrated Review
Group
<bullet> Cell Biology Integrated Review Group
<bullet> Center for Scientific Review Special Emphasis Panel
<bullet> Council of Councils
<bullet> Cures Acceleration Network Review Board
<bullet> Digestive, Kidney and Urological Systems Integrated Review
Group
<bullet> Division of Intramural Research Board of Scientific Counselors
National Institute of Allergy and Infectious Diseases
<bullet> Emerging Technologies and Training Neurosciences Integrated
Review Group
<bullet> Endocrinology, Metabolism, Nutrition and Reproductive Sciences
Integrated Review Group
<bullet> Fogarty International Center Advisory Board
<bullet> Genes, Genomes, and Genetics Integrated Review Group
<bullet> Healthcare Delivery and Methodologies Integrated Review Group
<bullet> Infectious Diseases and Immunology A Integrated Review Group
<bullet> Infectious Diseases and Immunology B Integrated Review Group
<bullet> Integrative, Functional and Cognitive Neuroscience Integrated
Review Group
<bullet> Interagency Autism Coordinating Committee
<bullet> Interagency Pain Research Coordinating Committee
<bullet> Interdisciplinary Molecular Sciences and Training Integrated
Review Group
<bullet> Molecular, Cellular and Developmental Neuroscience Integrated
Review Group
<bullet> Muscular Dystrophy Coordinating Committee
<bullet> Musculoskeletal, Oral, and Skin Sciences Integrated Review
Group
<bullet> National Advisory Allergy and Infectious Diseases Council
<bullet> National Advisory Board on Medical Rehabilitation Research
<bullet> National Advisory Child Health and Human Development Council
<bullet> National Advisory Council for Biomedical Imaging and
Bioengineering
<bullet> National Advisory Council for Complementary and Integrative
Health
<bullet> National Advisory Council for Human Genome Research
<bullet> National Advisory Council for Nursing Research
<bullet> National Advisory Council on Aging
<bullet> National Advisory Council on Alcohol Abuse and Alcoholism
<bullet> National Advisory Council on Drug Abuse
<bullet> National Advisory Council on Minority Health and Health
Disparities
<bullet> National Advisory Dental and Craniofacial Research Council
<bullet> National Advisory Environmental Health Sciences Council
<bullet> National Advisory Eye Council
<bullet> National Advisory General Medical Sciences Council
<bullet> National Advisory Mental Health Council
<bullet> National Advisory Neurological Disorders and Stroke Council
<bullet> National Arthritis and Musculoskeletal and Skin Diseases
Advisory Council
<bullet> National Cancer Advisory Board
<bullet> National Cancer Institute Clinical Trials and Translational
Research Advisory Committee
<bullet> National Cancer Institute Council of Research Advocates
<bullet> National Center for Advancing Translational Sciences Advisory
Council
<bullet> National Deafness and Other Communication Disorders Advisory
Council
<bullet> National Diabetes and Digestive and Kidney Diseases Advisory
Council
<bullet> National Heart, Lung, and Blood Advisory Council
<bullet> National Science Advisory Board for Biosecurity
<bullet> National Toxicology Program Board of Scientific Counselors
<bullet> National Toxicology Program Special Emphasis Panel
<bullet> NIH Clinical Center Research Hospital Board
<bullet> Office of AIDS Research Advisory Council
<bullet> Office of Research Infrastructure Programs Special Emphasis
Panel
<bullet> Oncology 1--Basic Translational Integrated Review Group
<bullet> Oncology 2--Translational Clinical Integrated Review Group
<bullet> Population Sciences and Epidemiology Integrated Review Group
<bullet> President's Cancer Panel
<bullet> Risk, Prevention and Health Behavior Integrated Review Group
<bullet> Scientific Advisory Committee on Alternative Toxicological
Methods
<bullet> Scientific and Technical Review Board on Biomedical and
Behavioral Research Facilities
<bullet> Scientific Management Review Board
<bullet> Sickle Cell Disease Advisory Committee
<bullet> Sleep Disorders Research Advisory Board
[[Page 51501]]
<bullet> Social and Community Influences on Health Integrated Review
Group
<bullet> Surgical Sciences, Biomedical Imaging and Bioengineering
Integrated Review Group
<bullet> Vaccine Research Center Board of Scientific Counselors
National Institute of Allergy and Infectious Diseases
<bullet> Vascular and Hematology Integrated Review Group
5. Justification that the information or advice provided by the
Federal advisory committee or subcommittee is not available from
another Federal advisory committee, another Federal Government source,
or any other more cost-effective and less burdensome source:
FICAB provides expert advice in global health research, training,
international collaboration, and research capacity strengthening that
is not available from other Federal Advisory Committees or government
sources. FIC Advisory Board members bring specialized scientific
expertise and extensive experience working internationally and
conducting global research. There is no comparable committee with the
unique combination of expertise in research and global health. The
independent expertise of the Board strengthens FIC's global health
research and training activities and helps to ensure these activities
align with U.S. and NIH health, security, and scientific policies and
goals.
The costs to convene FICAB are described in response to item #1.
The Board conducts the statutorily required second-level review of
grant applications, ensuring appropriate evaluation of funding
recommendations following initial peer review. This grant review cannot
be conducted through more cost-effective or less burdensome alternative
mechanisms.
6. If the consultation is a committee renewal, a summary of the
previous accomplishments of the committee and the reasons it needs to
continue:
FIC's uniquely international mission requires external expertise to
support sound decision-making, responsible use of public funds, and
alignment with U.S. priorities. The Board has played a key role in
shaping FIC's strategic direction, program priorities, and funding
decisions. Its guidance has helped to ensure that FIC's portfolio
remains rigorous, relevant, and aligned with NIH and HHS priorities.
The Board has also provided advice to shape NIH global research that
has helped position the U.S. as a global leader in biomedical research.
7. Explanation of why the committee/subcommittee is essential to
the conduct of agency business:
FIC is essential to agency operations because it fulfills the
required second-level review of FIC grant applications, as required
under section 492 of the PHS Act. The Board also provides critical
advice to the NIH Director and FIC Director on scientific,
programmatic, and policy matters related to global health research. The
Board advises on research investments and international collaborations
that strengthen global capacity to detect, prevent, and respond to
emerging health threats, thereby supporting U.S. health security. It
also provides insight on program design and performance to ensure FIC's
initiatives promote scientific excellence and responsible oversight of
federal resources. This independent guidance ensures that FIC's
portfolio aligns with U.S. health, security, and scientific policies
and goals to make America safer, stronger and more prosperous.
In conclusion, this public interest determination documents that
renewing the committee is in the public interest, essential to the
conduct of agency business, and that the information to be obtained is
not already available through another advisory committee or source
within the Federal Government.
Inquiries may be directed to Patricia Brandt Hansberger, Acting
Director, Office of Federal Advisory Committee Policy, Office of the
Director, National Institutes of Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301)
496-2123, or <a href="/cdn-cgi/l/email-protection#c1b1a0b5b3a8a2a8a0efa9a0afb2a3a4b3a6a4b381afa8a9efa6aeb7"><span class="__cf_email__" data-cfemail="24544550564d474d450a4c454a57464156434156644a4d4c0a434b52">[email protected]</span></a>.
Dated: August 4, 2026.
Margaret N. Vardanian,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2026-16257 Filed 8-7-26; 8:45 am]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 10, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.